Exhibit 10.1


 


VOTING AGREEMENT


 


THIS VOTING AGREEMENT (this “Agreement”)
is made and entered into as of December 5, 2019, by and between Cerecor, Inc., a Delaware corporation (“Cerecor”),
Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”), and the undersigned holders (each a “Holder”
and collectively the “Holders”). Cerecor, Aevi and the Holders are sometimes referred to herein collectively
as the “Parties” and individually as a “Party.” For the purposes of this Agreement, capitalized
terms used and not defined herein shall have the respective meanings ascribed to such terms as set forth in the Merger Agreement.


 


RECITALS:


 


A.       WHEREAS,
the number of shares of Common Stock and/or Options, as applicable, of Aevi, owned of record and beneficially by each of the Holders
is set forth opposite their names on Schedule A hereto (collectively referred to herein as the “Subject Securities”).


 


B.       WHEREAS,
on the date hereof, Cerecor and Aevi, among others, have entered into an Agreement and Plan of Merger (the “Merger Agreement”).


 


C.       WHEREAS,
after the effective time, a Holder might acquire additional shares of Common Stock and/or Options, as applicable, of Aevi (any
such securities so acquired, the “Acquired Securities,” and together with the Subject Securities, the “Securities”)


 


D.       WHEREAS,
as a condition to the willingness of Cerecor and Aevi to enter into the Merger Agreement and as a material inducement and in consideration
therefor, each Holder has agreed to enter into this Agreement.


 


NOW THEREFORE, in consideration of the promises
and the covenants and agreements set forth below, and for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereby agree as follows:


 


1.       
Agreement to Vote Shares. At any meeting of stockholders of Aevi or at any adjournment thereof that may take place
between now and Termination Date (the “Agreement Period”), in any action by written consent or in any other
circumstances upon which any Holder’s vote, consent or other approval related to the Merger Agreement is sought during the
Agreement Period, each Holder shall vote (or cause to be voted), as applicable, all of the Securities that are then entitled to
be voted (i) in favor of the Merger Agreement and the proposed transactions set forth in the Merger Agreement and (ii) against
any proposal, amendment, matter or agreement that would in any manner impede, frustrate, prevent or nullify the Merger Agreement.
Each Holder agrees that the Securities that are entitled to be voted shall be voted (or caused to be voted) as set forth in the
preceding sentences if each Holder’s vote, consent or other approval is sought and at any time or at multiple times during
the term of this Agreement.


 


2.       
Lock-up of Subject Securities. During the period beginning from the date hereof and continuing until the earlier
of (a) the expiration of the Agreement Period, or (b) the approval by the Aevi stockholders of the Merger Agreement and the transactions
contemplated thereby, each Holder agrees not to (i) offer, sell, contract to sell, pledge, grant any option to purchase, make any
short sale or otherwise transfer or dispose of, directly or indirectly any shares of common stock of Aevi, including the Subject
Securities or any Acquired Securities, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any
of the voting power or economic consequences of ownership of the common stock of Aevi (collectively, a “Transfer”),
without the prior written consent of both Cerecor and Aevi; provided, however, that this Agreement shall not restrict
Transfers, (i) if Holder is an individual, to any members of such Holder’s immediate family, a family trust of such Holder
or a charitable institution, (ii) if Holder is an entity, to any corporation, partnership, limited liability company, trust or
other business entity that is an Affiliate of such Holder, (iii) in connection
with the “net” or “cashless” exercise or settlement of any warrants, stock options, restricted stock units
or other equity awards (including any transfer for the payment of taxes due as a result of such vesting or exercise whether by
means of a “net settlement” or otherwise) or conversion of any convertible notes pursuant to any outstanding securities,
only if in each case prior to the effectiveness of the Transfer, the permitted transferee of such shares of common stock of Aevi
agrees in writing to be bound by the terms hereof (or an agreement that is substantively identical to this Agreement).


 






     


     


    

 


3.       
Opportunity to Review. Each Holder acknowledges receipt of the Merger Agreement and represents that he, she, or it
has had (i) the opportunity to review, and has read, reviewed and understands, the terms and conditions of the Merger Agreement
and this Agreement, and (ii) the opportunity to review and discuss the Merger Agreement and this Agreement with his, her or its
own advisors and legal counsel.


 


4.       
Representations and Warranties of Holder. Each Holder hereby represents and warrants as follows:


 


(a)          
Such Holder (i) is the record and beneficial owner of its Subject Securities, free and clear of any liens, adverse claims,
charges or other encumbrances of any nature whatsoever (other than pursuant to (x) restrictions on transfer under applicable securities
laws, or (y) this Agreement), and (ii) does not beneficially own any securities of Aevi (including options, warrants or convertible
securities) other than the Subject Securities and that certain Secured Convertible Promissory Note, dated as of March 29, 2019,
as amended to date, between Aevi and The Children’s Hospital of Philadelphia.


 


(b)          
Such Holder has the sole right to transfer, to vote (or cause to vote) and to direct (or cause to direct) the voting of
the Subject Securities, and none of the Subject Securities are subject to any voting trust or other agreement, arrangement or restriction
with respect to the transfer or the voting of the Subject Securities (other than restrictions on transfer under applicable securities
laws), except as set forth in this Agreement.


 


(c)           
Such Holder, if it is an entity, has all requisite power and authority or, if such Holder is an individual, has the legal
capacity, to execute and deliver this Agreement and to consummate the transactions contemplated hereby.


 


(d)          
This Agreement has been duly executed and delivered by such Holder and constitutes a valid and binding obligation of such
Holder and, assuming due authorization, execution and delivery by the other Parties hereto, is enforceable against such Holder
in accordance with its terms.


 






    2


     


    

 


(e)          
There is no Action pending or, to the knowledge of such Holder, threatened in writing against such Holder at law or equity
before or by any Governmental Entity that could reasonably be expected to impair or materially delay the performance by such Holder
of its obligations under this Agreement or otherwise adversely impact such Holder’s ability to perform its obligations hereunder.


 


5.       
Termination. This Agreement shall terminate automatically upon the approval of the Merger Agreement by Aevi’s
stockholders; provided, however, that this Agreement will also terminate (such date, the “Termination Date”)
if Cerecor or Aevi has (i) terminated the Merger Agreement in accordance with its terms prior to approval of the Merger Agreement
by Aevi’s stockholders or (ii) made any modification, waiver or amendment to the Merger Agreement (including the form of
CVR Agreement attached thereto) in a manner that reduces the amount or changes the form of consideration payable thereunder to
any Holder. In the event of the termination of this Agreement, this Agreement shall forthwith become null and void, there shall
be no liability on the part of any of the Parties, and all rights and obligations of each Party hereto shall cease; provided,
however, that no such termination of this Agreement shall relieve any Party hereto from any liability for any willful and
material breach of any provision of this Agreement prior to such termination, and this Section 5 shall survive any such termination.


 


6.       
Further Covenants and Assurances. During the term of this Agreement, each Holder hereby, to the extent permitted
by Laws, waives and agrees not to exercise any dissenters’ or appraisal rights, or other similar rights, with respect to
any Subject Securities which may arise in connection with the transactions contemplated by the Merger Agreement, nor to bring any
claim or join any lawsuit against Aevi, Cerecor or their respective affiliates with respect to the Merger Agreement or the transactions
contemplated thereby. During the term of this Agreement, each Holder shall deliver a written certificate to Aevi and Cerecor if
he, she, or it acquires any Acquired Securities, which certificate will (i) state the number of Acquired Securities so acquired,
and (ii) certify that the terms of this Agreement apply in all respects to the Acquired Securities.


 


7.       
Successors, Assigns and Transferees Bound. Without limiting Section 1 hereof in any way, each Holder agrees that
this Agreement and the obligations hereunder shall attach to the Subject Securities from the date hereof through the termination
of this Agreement and shall, to the extent permitted by applicable Laws, be binding upon any Person to which legal or beneficial
ownership of the Subject Securities shall pass, whether by operation of law or otherwise, including such Holder’s heirs,
guardians, administrators or successors, and each Holder further agrees to take all reasonable actions necessary to effectuate
the foregoing.


 


8.       
Capacity as a Holder. Each Holder is signing this Agreement in such Holder’s capacity as an owner of such Holder’s
Subject Securities, and nothing in this Agreement shall prohibit, prevent or preclude such Holder or its Representatives from taking
or not taking any action in its capacity as an officer or director of Aevi.


 






    3


     


    

 


9.       
Remedies. Each Holder acknowledges that money damages would be both incalculable and an insufficient remedy for any
breach of this Agreement by it, and that any such breach would cause Cerecor and Aevi irreparable harm. Accordingly, each Holder
agrees that in the event of any breach or threatened breach of this Agreement, Cerecor and Aevi, in addition to any other remedies
at law or in equity each may have, shall be entitled to seek immediate equitable relief, including injunctive relief and specific
performance, without the necessity of proving the inadequacy of money damages as a remedy and without the necessity of posting
any bond or other security, to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in
any court of the United States or any state having jurisdiction.


 


10.    
 Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given when personally delivered, or if sent by United States certified mail, return receipt requested, postage prepaid, shall be
deemed duly given on delivery by United States Postal Service, or if sent by e-mail or receipted overnight courier services shall
be deemed duly given on the Business Day received if received prior to 5:00 p.m. local time or on the following Business Day if
received after 5:00 p.m. local time or on a non-Business Day, addressed to the respective Parties as follows:


 


		(i)	if to Cerecor, to:



 


Cerecor, Inc.


540 Gaither Road, Suite 400


Baltimore, MD 20850


Attention: Joseph Miller


Email: jmiller@cerecor.com


 


with a required copy (which shall
not constitute notice) to:


 


Wyrick Robbins Yates & Ponton LLP


4101 Lake Boone Trail, Suite 300


Raleigh, NC 27607


Attention: Don Reynolds


Email: dreynolds@wyrick.com


 








		(ii)	if to Aevi, to:



 


Aevi Genomic Medicine, Inc.


435 Devon Park Drive, Suite 715

Wayne, PA 19087


Attention: Michael F. Cola


Email: mike.cola@aevigenomics.com


 


with a required copy (which shall
not constitute notice) to:


 


Pepper Hamilton LLP


3000 Two Logan Square


Philadelphia, PA 19103


Attention: Brian M. Katz


E-mail: katzb@pepperlaw.com


 






    4


     


    

 


		(iii)	if to a Holder, to the address set forth on the Holder’s signature pages hereto, with a required copy (which shall not
constitute notice) to:



 


Cooley LLP


55 Hudson Yards


New York, NY 10001


Attention: Josh Kaufman and Jeffrey
P. Libson


E-Mail: josh.kaufman@cooley.com


jlibson@cooley.com


 


11.     
Severability. Any provision hereof that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and
any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any
other jurisdiction. To the extent permitted by Law, each Party hereby waives any provision of Law that renders any such provision
prohibited or unenforceable in any respect.


 


12.     
Entire Agreement/Amendment. This Agreement (including the provisions of the Merger Agreement referenced herein) represent
the entire agreement of the Parties with respect to the subject matter hereof and supersede all prior agreements and understandings,
both written and oral, among the Parties with respect to the subject matter hereof. This Agreement may not be amended, modified,
altered or supplemented except by means of a written instrument executed and delivered by the Parties hereto.


 


13.     
No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in Cerecor any direct or indirect
ownership or incidence of ownership of or with respect to the Subject Securities. All rights, ownership and economic benefits of
and relating to the Subject Securities shall remain vested in and belong to each applicable Holder, and Cerecor shall not have
any authority to manage, direct, restrict, regulate, govern, or administer any of the policies or operations of Aevi or exercise
any power or authority to direct such Holder in the voting of any of the Subject Securities, except as otherwise provided herein.


 






    5


     


    

 


14.     
Governing Law. This Agreement, and all claims or causes of action (whether in contract, tort or otherwise) that may
be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance of this Agreement, shall be
governed by and construed in accordance with the internal Laws of the State of Delaware without reference to its choice of law
rules. Each Party agrees that any legal action or other legal proceeding relating to this Agreement or the enforcement of any provision
of this Agreement shall be brought or otherwise commenced exclusively in the Court of Chancery of the State of Delaware or any
federal court of competent jurisdiction in the State of Delaware. Each of the Parties consents to service of process in any such
proceeding in any manner permitted by the Laws of the State of Delaware, and agrees that service of process by registered or certified
mail, return receipt requested, at its address specified pursuant to Section 10 of this Agreement is reasonably calculated to give
actual notice. Each Party waives and agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding
commenced in such courts, any claim that such Party is not subject personally to the jurisdiction of such courts, that such legal
proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the
subject matter hereof or thereof may not be enforced in or by such courts. EACH PARTY HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL
BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO
THIS AGREEMENT OR THE ACTIONS OF SUCH PARTY IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.


 


15.     
Counterparts. This Agreement may be executed by delivery of electronic signatures and in two or more counterparts,
each of which shall be deemed an original, and it shall not be necessary in making proof of this Agreement or the terms hereof
to produce or account for more than one of such counterparts.


 


[SIGNATURE
PAGES FOLLOW]


 






    6


     


    

 


In
Witness Whereof, the Parties have caused this Agreement to be executed as of the date first above written.


  


	 	CERECOR, Inc.
	 
	 	By:	 
	 	Name:
	 	Title:






 


	 	Aevi Genomic Medicine, Inc.
	 	 
	 	By:	 
	 	Name:
	 	Title:












 





[Signature Page to Voting Agreement]


 








     


     


    

 


	 	The Children’s Hospital of Philadelphia Foundation
	 	 
	 	By:	 
	 	Name:
	 	Title:




 



	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 








 







[Signature Page to Voting Agreement]


 



     


     


    




 


	 	 	 
	 	Sol J. Barer




 





	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 


 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Eugene A. Bauer	 




 





	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 


 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Alastair Clemow	 




 





	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 


 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Michael F. Cola	 




 





	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 


 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Barbara G. Duncan	 




 


	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 





 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Joseph J. Grano, Jr.	 




 





	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 


 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Garry A. Neil	 




 





	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 


 


[Signature Page to Voting Agreement]


 






     


     


    

 


	 	 	 
	 	Michael H. McInaw	 



 


	 	Address:	 
	 	 	 
	 	 	 
	 	 	 
	 	Email:	 





 


[Signature Page to Voting Agreement]


 






     


     


    

 






SCHEDULE A


 


	Name	 	Common Stock	 	 	Options	 
	The Children’s Hospital of Philadelphia Foundation	 	 	18,424,036	 	 	 	90,000	 
	Sol J. Barer*	 	 	4,098,752	 	 	 	1,170,000	 
	Eugene A. Bauer	 	 	165,715	 	 	 	188,571	 
	Alastair Clemow	 	 	57,536	 	 	 	230,714	 
	Michael F. Cola*	 	 	218,483	 	 	 	2,754,582	 
	Barbara G. Duncan	 	 	59,524	 	 	 	130,000	 
	Joseph J. Grano, Jr.	 	 	174,847	 	 	 	125,000	 
	Garry A. Neil*	 	 	114,774	 	 	 	1,765,644	 
	Michael H. McInaw	 	 	16,107	 	 	 	29,416	 



 


* On
the date hereof, Drs. Barer and Neil and Mr. Cola entered into an agreement pursuant to which Dr. Barer sold all of his shares
of Aevi Common Stock to Dr. Neil and Mr. Cola resulting in Dr. Barer owning no shares, Mr. Cola owning 2,267,859 shares and Dr.
Neil owning 2,164,150 shares of Aevi Common Stock.